More than half of patients with microsatellite-stable metastatic colorectal cancer without active liver metastases survived at least 18 months with botensilimab plus balstilimab.
|Articles|January 1, 2003
Oncology NEWS International
- Oncology NEWS International Vol 12 No 1
- Volume 12
- Issue 1
CMS Helps States Create High-Risk Pools for Health Care Coverage
WASHINGTON-A new federal program will help some states create high-risk pools to extend health care coverage to people whose health status makes it difficult for them to obtain medical insurance. Under the program, the Centers for Medicare & Medicade Services (CMS) will provide seed grants of up to $1 million to support creation of the programs in 27 states that currently do not have qualified high-risk pools and in the District of Columbia. Typically, such pools are state-created nonprofit associations. The new program was authorized in the Trade Law of 2002, which appropriated $20 million to fund the grants.
Advertisement
WASHINGTONA new federal program will help some states create high-risk pools to extend health care coverage to people whose health status makes it difficult for them to obtain medical insurance. Under the program, the Centers for Medicare & Medicade Services (CMS) will provide seed grants of up to $1 million to support creation of the programs in 27 states that currently do not have qualified high-risk pools and in the District of Columbia. Typically, such pools are state-created nonprofit associations. The new program was authorized in the Trade Law of 2002, which appropriated $20 million to fund the grants.
Articles in this issue
almost 24 years ago
Phase II Trial of Phenoxodiol in Recurrent Ovarian Cancer Is launchedalmost 24 years ago
FDA Approves New Taxotere Indication as First-Line Therapy for NSCLCalmost 24 years ago
Most Cancer Pain Is Experienced at the Patient’s Homealmost 24 years ago
HHS Unites Its HIV Advisorsalmost 24 years ago
First NCI Health Disparity Grantsalmost 24 years ago
Pain Therapy Improves Quality of Life for Caregiversalmost 24 years ago
Inex to Seek FDA Approval for Onco TCS (Liposomal Vincristine)almost 24 years ago
CD40L-Expressing Dendritic Cells Eliminate Breast Tumors in Micealmost 24 years ago
Safe Handling Tips for Use of Testosterone Gelalmost 24 years ago
Lumpectomy/Mastectomy Equivalent in Early Breast CancerAdvertisement
Related to this article
Investigators will present detailed findings from a phase 2 study assessing a tambiciclib-based regimen in patients with relapsed/refractory AML at ASH 2026.
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he considers it the better option.
Chinmay Jani, MD, discusses ASCO 2026 data on lung cancer trends in younger adults and why this group has been overlooked.
Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC
3
Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC
4
Air Pollution Emerges as Second Leading Risk Factor for Lung Cancer Deaths
5